Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Enzalutamide or PD-1 Inhibitor After BAT for mCRPC
ChiCTR2600125798Phase 3Not yet recruiting
- Sponsor
- Beijing Hospital
- Start
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Abiraterone + Prednisone control, BAT → Enzalutamide and BAT → Toripalimab (3 arms). Primary endpoint: Disease progression. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
enzalutamidetoripalimababiraterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on ChiCTR2600125798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125798.